11/8/26 Ultra-Rare, Ultra-Lean: Designing for a Viable ROI Under 1,000 Patients Previous Pediatric Rare Disease Development: Evidence, Flexibility, and Regulatory Pathways Next Inside the FDA Mindset - Negotiating Endpoints and Surrogates You Might Also Like From Awareness to Activation - Converting Rare Patient Identification into Trial Enrollment Retention by Design - Keeping Families Engaged for Multi-Year Studies Learning More from Less: Smarter Design and Execution in Rare Disease Trials Designing Neuromuscular Trials for Successful Execution: The Role of Specialized CROs, Sites and Clinical Research Vendors Inside the FDA Mindset - Negotiating Endpoints and Surrogates
11/8/26 Ultra-Rare, Ultra-Lean: Designing for a Viable ROI Under 1,000 Patients Previous Pediatric Rare Disease Development: Evidence, Flexibility, and Regulatory Pathways Next Inside the FDA Mindset - Negotiating Endpoints and Surrogates You Might Also Like From Awareness to Activation - Converting Rare Patient Identification into Trial Enrollment Retention by Design - Keeping Families Engaged for Multi-Year Studies Learning More from Less: Smarter Design and Execution in Rare Disease Trials Designing Neuromuscular Trials for Successful Execution: The Role of Specialized CROs, Sites and Clinical Research Vendors Inside the FDA Mindset - Negotiating Endpoints and Surrogates
